Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Y Cheng, C He, M Wang, X Ma, F Mo, S Yang… - Signal transduction and …, 2019‏ - nature.com
Epigenetic alternations concern heritable yet reversible changes in histone or DNA
modifications that regulate gene activity beyond the underlying sequence. Epigenetic …

Up-down regulation of HIF-1α in cancer progression

M Rashid, LR Zadeh, B Baradaran, O Molavi… - Gene, 2021‏ - Elsevier
Hypoxia induicible factor-1 alpha (HIF-1α) is a key transcription factor in cancer progression
and target therapy in cancer. HIF-1α acts differently depending on presence or absence of …

METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer

B Yue, C Song, L Yang, R Cui, X Cheng, Z Zhang… - Molecular cancer, 2019‏ - Springer
Background As one of the most frequent chemical modifications in eukaryotic mRNAs, N6-
methyladenosine (m6A) modification exerts important effects on mRNA stability, splicing …

Hallmarks of cancer—the new testament

SS Senga, RP Grose - Advances in Surgical and Medical …, 2023‏ - taylorfrancis.com
Ancient Egyptians believed cancer to be a curse, as seen from evidence as old as 3000 BC
from the Edwin Smith Papyrus which described breast cancer and Ebers Papyrus dated …

[HTML][HTML] β-Sitosterol as a promising anticancer agent for chemoprevention and chemotherapy: mechanisms of action and future prospects

H Wang, Z Wang, Z Zhang, J Liu, L Hong - Advances in Nutrition, 2023‏ - Elsevier
Cancer is one of the primary causes of death worldwide, and its incidence continues to
increase yearly. Despite significant advances in research, the search for effective and …

Context-dependent EMT programs in cancer metastasis

NM Aiello, Y Kang - Journal of Experimental Medicine, 2019‏ - rupress.org
Epithelial–mesenchymal transition (EMT) is a developmental process whereby stationary,
adherent cells acquire the ability to migrate. EMT is critical for dramatic cellular movements …

HDACs and HDAC inhibitors in cancer development and therapy

Y Li, E Seto - Cold Spring Harbor perspectives in …, 2016‏ - perspectivesinmedicine.cshlp.org
Over the last several decades, it has become clear that epigenetic abnormalities may be one
of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play …

Cancer metastasis: molecular mechanisms and clinical perspectives

SU Khan, K Fatima, F Malik, H Kalkavan… - Pharmacology & …, 2023‏ - Elsevier
Metastatic progression combined with non-responsiveness towards systemic therapy often
shapes the course of disease for cancer patients and commonly determines its lethal …

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas

MK Jolly, JA Somarelli, M Sheth, A Biddle… - Pharmacology & …, 2019‏ - Elsevier
Cancer metastasis and therapy resistance are the major unsolved clinical challenges, and
account for nearly all cancer-related deaths. Both metastasis and therapy resistance are …

Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment

C Falcomata, S Baerthel, SA Widholz, C Schneeweis… - Nature Cancer, 2022‏ - nature.com
KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) is highly immunosuppressive and
resistant to targeted and immunotherapies. Among the different PDAC subtypes, basal-like …